The present review aims to present currently available evidence regarding the cardiovascular efficacy and safety of SGLT-2 inhibitors and GLP-1 receptor agonists in the setting of ACS affecting patients with and without concomitant DM (Fig. 1). The gene discussed is GLP1R; the disease is diabetes mellitus.